This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}}
{{headerpanel|{{Approval}}}}
{{headerpanel|{{Approval}}}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/Example}}
{{SubstanceBox/Cariprazine}}
'''Cariprazine''' (sold under the brand names '''Vraylar''' and '''Reagila''' among others) is an atypical antipsychotic originated by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder.
<!-- Please ensure that any new substance articles are first published in the 'Talk' namespace. For example, a new article on substance XYZ should have the title "Talk: XYZ" instead of "XYZ". Once the submitted article has been reviewed and determined to meet the guidelines and standards, it will be published by a staff member. -->
For tips on how to properly format a substance article, please refer to this document: [[Content Style Guide - Substance]]
==History and culture==
==History and culture==
Line 16:
Line 10:
==Chemistry==
==Chemistry==
Cariprazine, sold under the brand names Vraylar and Reagila among others, is an atypical antipsychotic originated by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder. It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor.[ It is taken by mouth.
{{Chemistry}}
==Pharmacology==
==Pharmacology==
{{pharmacology}}
It acts primarily as a D<sub>3</sub> and D<sub>2</sub> receptor partial agonist, with a preference for the D<sub>3</sub> receptor. Cariprazine is also a partial agonist at the serotonin 5-HT<sub>1A</sub> receptor and acts as an antagonist at 5-HT<sub>2B</sub> and 5-HT<sub>2A</sub> receptors, with high selectivity for the D<sub>3</sub> receptor.
==Subjective effects==
==Subjective effects==
Line 36:
Line 30:
}}
}}
{{effects/visual|
If applicable, a brief paragraph summary of the substance's visual effects may be included here.
You may select visual effects to add below [[Subjective effect index#Visual effects|here]].
====Enhancements====
*'''[[Effect::Visual acuity effect1]]'''
====Distortions====
*'''[[Effect::Visual distortion effect1]]'''
====[[Effect::Geometry]]====
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
====Hallucinatory states====
If applicable, a brief summary of the substance's visual effects profile may be written here.
*'''[[Effect::Hallucinatory states1]]'''
}}
|{{effects/cognitive|
|{{effects/cognitive|
If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
Line 64:
Line 38:
*'''[[Effect::Cognitive effect2]]'''
*'''[[Effect::Cognitive effect2]]'''
*'''[[Effect::Cognitive effect3]]'''
*'''[[Effect::Cognitive effect3]]'''
}}
{{effects/auditory|
If applicable, a brief paragraph summary of the substance's auditory effects may be included here.
You may select from a list of auditory effects to add below [[Subjective effect index#Auditory effects|here]].
*'''[[Effect::Auditory effect1]]'''
*'''[[Effect::Auditory effect2]]'''
}}
{{effects/multisensory|
If applicable, a brief paragraph summary of the substance's multisensory effects may be included here.
You may select from a list of multisensory effects to add below [[Subjective effect index#Multisensory effects|here]].
*'''[[Effect::Multisensory effect1]]'''
*'''[[Effect::Multisensory effect2]]'''
}}
{{effects/transpersonal|
If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here.
You may select from a list of transpersonal effects to add below [[Subjective effect index#Transpersonal effects|here]].
*'''[[Effect::Transpersonal effect1]]'''
*'''[[Effect::Transpersonal effect2]]'''
}}
}}
}}
}}
===Experience reports===
===Experience reports===
There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
There are currently {{#ask:[[Category:Cariprazine]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]].
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
Cariprazine (sold under the brand names Vraylar and Reagila among others) is an atypical antipsychotic originated by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder.
Cariprazine is used to treat patients with schizophrenia and manic, depressive, or mixed episodes associated with bipolar I disorder. In the United States it is approved for schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).
Cariprazine consistently improved depressive symptoms across a spectrum of patients with bipolar I depression. In Australia, the United Kingdom, and the European Union it is approved only for treating schizophrenia.
It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
If applicable, a brief paragraph summary of the substance's physical effects may be included here.
You may select physical effects to add below here.
If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
You may select from a list of cognitive effects to add below here.
There are currently 0 experience reports which describe the effects of this substance in our experience index.
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
